Chemomab

The Challenge

Fibrosis-related diseases are a significant unmet need that dramatically affect patients' health and quality of life.

Damaged tissue repairs itself through a sequence of controlled inflammatory and fibrotic processes. However, uncontrolled healing processes can create a vicious cycle of inflammation and fibrosis – an excessive, sustained, chronic inflammatory response that activates fibroblasts, and replaces functional tissue with fibrous scar tissue.

CCL24 - a Key Player

Regulating CCL24 is key to halting fibrosis-related conditions

Chemomab discovered that the soluble protein CCL24 plays a key role in promoting inflammation and fibrosis via a dual pathway. CCL24 promotes both the recruitment of immune cells to the damaged tissue and supports its polarization to create a pro-fibrotic environment. In parallel, CCL24 directly activates tissue fibroblasts, enhances their transition into myofibroblasts and induces the uncontrolled production of extracellular matrix.

CM-101 Therapeutic Platform

Pioneering innovation to treat fibrosis-related diseases.

Chemomab’s lead compound, CM-101 is a first-in-class humanized monoclonal antibody designed to bind to and neutralize CCL24 activity.

CM-101 interferes with the main pathologies that promote fibrosis and inflammation. It is highly effective in ameliorating fibrosis, as shown across multiple in vivo, in vitro and ex vivo studies, including experimental models of liver, skin and lung fibrosis. Chemomab has reported positive topline data from the CM-101 Phase 2 SPRING trial in patients with primary sclerosing cholangitis (PSC), a rare, potentially lethal disease of the bile ducts. It also has demonstrated encouraging biomarker data in a Phase 2a liver fibrosis trial in patients with metabolic-associated steatohepatitis (MASH), as well as activity in multiple preclinical models of systemic sclerosis (SSc).

To learn more about how CM-101 may interrupt the fibro-inflammatory vicious cycle believed to drive disease progression in PSC, see our Mechanism of Action (MOA) video at MOA video